Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma renal crisis.

Virginia D Steen1

  • 1Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Georgetown University, 3800 Reservoir Road, NW-LL Gorman, Washington, DC 20007, USA. steenv@georgetown.edu

Rheumatic Diseases Clinics of North America
|July 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

The Journal of rheumatology·2025
Same author

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.

Rheumatology (Oxford, England)·2025
Same author

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Annals of the American Thoracic Society·2025
Same journal

Rheumatology at the Threshold of Artificial Intelligence.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence Regulation in the United States: Current Landscape and Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

The Role of Artificial Intelligence in Medical Education and Training: Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Sources of Bias in Clinical Artificial Intelligence and Applications in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Toward Bridging the Gap from Artificial Intelligence in Clinical Research to Clinical Practice in Rheumatology: The Mayo Experience.

Rheumatic diseases clinics of North America·2026
See all related articles

Systemic sclerosis renal crisis (SRC) is a severe complication. Early treatment with ACE inhibitors significantly improves survival and kidney function, often avoiding long-term dialysis.

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) can lead to a life-threatening complication known as scleroderma renal crisis (SRC).
  • SRC is characterized by severe hypertension, kidney dysfunction, and anemia, historically associated with high mortality.
  • Early diffuse cutaneous thickening in SSc patients indicates a higher risk for developing SRC.

Purpose of the Study:

  • To highlight the critical role of early diagnosis and prompt treatment of scleroderma renal crisis.
  • To emphasize the effectiveness of angiotensin-converting enzyme (ACE) inhibitors in managing SRC.
  • To inform clinicians about the improved outcomes and potential for dialysis independence with timely intervention.

Main Methods:

  • Review of clinical characteristics and outcomes of patients with systemic sclerosis and renal crisis.

Related Experiment Videos

  • Analysis of treatment responses to angiotensin-converting enzyme (ACE) inhibitors.
  • Evaluation of the impact of ACE inhibitor therapy on patient survival and renal function.

    • Main Results:

    • Scleroderma renal crisis (SRC) is now treatable with angiotensin-converting enzyme (ACE) inhibitors, dramatically improving outcomes.
    • ACE inhibitor therapy leads to better survival rates, reduced need for dialysis, and potential for dialysis discontinuation within 6-18 months.
    • Prompt diagnosis and aggressive initiation of ACE inhibitor treatment are crucial for optimal patient outcomes.

    Conclusions:

    • Angiotensin-converting enzyme (ACE) inhibitors represent a highly effective treatment for scleroderma renal crisis (SRC).
    • Early and aggressive management of SRC with ACE inhibitors can prevent irreversible renal damage and improve long-term prognosis.
    • Timely intervention is key to transforming the prognosis of this previously fatal complication of systemic sclerosis.